



## Expert Updates in the Management of AML and CLL

### Target Audience:

Professions: Physician (MD or DO), Nurse/APN, Pharmacist

### Description:

Activity addressing the clinical context and implications with case presentations about the shifts in the treatment paradigms, new drug approvals, and emerging agents in the areas of AML and CLL.

**Initial Release Date:** 09/28/2021

**Expiration Date:** 09/28/2022

**Estimated Time to Complete** 1.00 hour(s)

### Accreditation:

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

### Credit Designation:

The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Commercial Support:

**SUPPORT ACKNOWLEDGEMENT:** The conference organizing committee wishes to express appreciation to the following companies for their commitment to continuing medical education by providing an educational grant in support of this conference: AbbVie Inc. Astellas Pharma Global Development, Inc. Janssen Scientific Affairs, LLC and Pharmacyclics LLC, an AbbVie Company

The University of Texas MD Anderson Cancer Center adheres to the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

### Faculty & Planner Disclosure:

Name of individual	Individual's role in activity	Name of commercial interest/Nature of relationship
Maher Karam-Hage, MD	Activity Director/Chair	Nothing to disclose
Courtney D DiNardo, MD	Faculty	Membership on advisory committees or review panels, board membership, etc.: Agios, Celgene, Abbvie; Stocks or stock options, excluding diversified mutual funds: Notable Labs; Honoraria: Novartis AG, Aprea, Gilead, Foghorn Therapeutics
Amir T Fathi, MD	Faculty	Paid consultant: Agios, Takeda Pharmaceuticals, Inc., Pfizer, Inc, Trillium, Abbvie, Kura, Blueprint, Astellas, Genentech, Inc, Foghorn, Bristol-Myers

		Squibb, Kite, Morphosys, Ipsen; Grant or research support: Agios, Bristol-Myers Squibb, Abbvie, Servier
John M. Pagel, MD, MD, PhD	Faculty	Paid consultant: AstraZeneca, Gilead, Incyte/Morphosys, Epizyme, Beigene, MEI Pharma, Actinium Pharmaceuticals
Philip Thompson, MBBS	Faculty	Membership on advisory committees or review panels, board membership, etc.: Adaptive Biotechnologies, AbbVie; Honoraria: Janssen
Angelic Castillo	Other Planning Committee Member	Nothing to disclose
Lisa Cockrell, PhD	Other Planning Committee Member	Nothing to disclose
Stephanie Corder, Doctor of Nursing	Other Planning Committee Member	Nothing to disclose
Brittney French , BS	Other Planning Committee Member	Nothing to disclose
Haleh Kadkhoda, MS	Other Planning Committee Member	Nothing to disclose
Amy A Sabek, MBA	Other Planning Committee Member	Nothing to disclose